Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Apolipoprotein B(ApoB) Reduction by ISIS 301012 on Liver Triglyceride Content in Subjects With Varying Degrees of Hyperlipidemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Mipomersen (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa; Hypobetalipoproteinaemia
- Focus Adverse reactions
- Sponsors Genzyme Corporation
- 01 Feb 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 01 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.